Document Detail

Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression.
MedLine Citation:
PMID:  20980705     Owner:  NLM     Status:  In-Process    
BACKGROUND AND AIMS: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombosis, obstetric complications and the presence of anti-phospholipid antibodies such as anti-β2GPI-Abs. These antibodies may set off the coagulation cascade via several mechanisms, including the induction of tissue factor (TF) expression. Vitamin D has recently emerged as an immunomodulator that might exert an anti-thrombotic effect. Therefore, we studied serum vitamin D levels in a cohort of APS patients, as well as the effect of vitamin D in an in vitro model of APS-mediated thrombosis.
METHODS: Serum vitamin D levels were measured in 179 European APS patients and 141 healthy controls using the LIAISON chemiluminescent immunoassay, and the levels were evaluated in conjunction with a wide spectrum of clinical manifestations. In an vitro model, anti-β2GPI antibodies were purified from four patients with APS to evaluate the expression of TF in activated starved human umbilical vein endothelial cells. The effect of vitamin D (1,25-dihydroxyvitamin D, 10 nm) on anti-β2GPI-Abs mediated TF expression was analysed by immunoblot.
RESULTS: Vitamin D deficiency (serum level ≤15 ng/ml) was documented in 49.5% of our APS patients versus 30% of controls (p<0.001) and was significantly correlated with thrombosis (58% vs 42%; p<0.05), neurological and ophthalmic manifestations, pulmonary hypertension, livedo reticularis and skin ulcerations. In vitro vitamin D inhibited the expression of TF induced by anti-β2GPI-antibodies.
CONCLUSIONS: Vitamin D deficiency is common among APS patients and is associated with clinically defined thrombotic events. Vitamin D inhibits anti-β2GPI-mediated TF expression in vitro. Thus, vitamin D deficiency might be associated with decreased inhibition of TF expression and increased coagulation in APS. Evaluation of vitamin D status and vitamin D supplementation in APS patients should be considered.
N Agmon-Levin; M Blank; G Zandman-Goddard; H Orbach; P L Meroni; A Tincani; A Doria; R Cervera; W Miesbach; L Stojanovich; V Barak; B S Porat-Katz; H Amital; Y Shoenfeld
Related Documents :
604625 - Tetracycline fluorescence in uremic and primary hyperparathyroid bone.
1396485 - Elevated plasma vitamers of vitamin b6 in patients with chronic renal failure on regula...
8426395 - Vitamin b12 deficiency in patients with ileocolic neobladders.
1341435 - Parathyroid function and bone metabolism in children with beta thalassaemia major: effe...
21452775 - Carotid intima-media thickness in patients with chronic obstructive pulmonary disease.
6806155 - Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hep...
Publication Detail:
Type:  Journal Article     Date:  2010-10-27
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  70     ISSN:  1468-2060     ISO Abbreviation:  Ann. Rheum. Dis.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  England    
Other Details:
Languages:  eng     Pagination:  145-50     Citation Subset:  IM    
The Zabludowicz Center for Autoimmune Diseases and Department of Medicine B, Sheba Medical Center, Tel Hashomer, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Fc? receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion r...
Next Document:  Sociocognitive self-regulatory mechanisms governing judgments of the acceptability and likelihood of...